Liver ischemia reperfusion injury (IRI) is an important problem in liver transplantation. Thrombomodulin (TM), an effective drug for disseminated intravascular coagulation, is also known to exhibit an anti-inflammatory effect through binding to the high-mobility group box 1 protein (HMGB-1) known as a proinflammatory mediator. We examined the effect of recombinant human TM (rTM) on a partial warm hepatic IRI model in wild-type (WT) and tolllike receptor 4 (TLR-4) KO mice focusing on the HMGB-1/TLR-4 axis. As in vitro experiments, peritoneal macrophages were stimulated with recombinant HMGB-1 protein. The rTM showed a protective effect on liver IRI. The rTM diminished the downstream signals of TLR-4 and also HMGB-1 expression in liver cells, as well as release of HMGB-1 from the liver. Interestingly, neither rTM treatment in vivo nor HMGB-1 treatment in vitro showed any effect on TLR-4 KO mice. Parallel in vitro studies have confirmed that rTM interfered with the interaction between HMGB-1 and TLR-4. Furthermore, the recombinant N-terminal lectin-like domain 1 (D1) subunit of TM (rTMD1) also ameliorated liver IRI to the same extent as whole rTM. Not only rTM but also rTMD1 might be a novel and useful medicine for liver transplantation. This is the first report clarifying that rTM ameliorates inflammation such as IRI in a TLR-4 pathway-dependent manner.
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Introduction
Ischemia reperfusion injury (IRI) is an important issue to solve for successful organ transplantation. In the case of liver transplantation, IRI causes approximately 10% of early graft failure and leads to a higher incidence of acute and chronic rejection. Thus, overcoming IRI contributes to an increase in the number of donor organs available for transplantation. However, the mechanisms underlying liver IRI are complex, and various factors are involved (1) .
Previous studies, including ours, have documented that toll-like receptor 4 (TLR-4) is expressed on various types of cells in mouse livers (2, 3) . TLR-4-dependent innate immune reactions are triggered upon liver IRI and cause the production of inflammatory cytokines mediated through activation of nuclear factor kappa B (NF-jB), followed by the development of inflammation in the liver (4, 5) . Thus, the endogenous TLR-4 ligand plays a crucial role in facilitating IRI-mediated liver inflammatory responses (6).
High-mobility group box 1 (HMGB-1) is an evolutionarily conserved nuclear protein that binds to chromatin and is involved in DNA organization and regulation of transcription (7, 8) . HMGB-1 is also released from necrotic cells (9) and inflammatory cells such as macrophages (10) . It has been reported that HMGB-1 is released into the extracellular space in the liver during IRI and causes the production of inflammatory cytokines (4) . Although the cytokine-like property of HMGB-1 was initially identified as a late mediator of lethality in the sepsis model, it has also been identified as an early mediator of inflammation. HMGB-1 appears to be the key endogenous ligand for TLR-4, which is responsible for the early stage of inflammatory responses during liver IRI (4, 5) .
Recombinant human soluble thrombomodulin (rTM) contains only the active extracellular domain of thrombomodulin (TM) (11) . This has been applied widely in clinical use for disseminated intravascular coagulation (DIC) treatment in Japan. A recent phase III trial showed that rTM is more effective and safer than low-dose heparin for the treatment of DIC (12) . In 2008, rTM was approved as a standard treatment for DIC in Japan. Some studies have shown that rTM also exhibits anti-inflammatory properties in addition to its anticoagulant effect (13) . The anti-inflammatory effect of rTM has been approved in studies using septic models (14) . Recently, rTM and the N-terminal lectin-like domain 1 of rTM (rTMD1) have been shown to play an important role in rTM's anti-inflammatory effect through binding to HMGB-1 (15) . Therefore, we hypothesized that the administration of rTM or rTMD1 may affect hepatic IRI by interfering with the HMGB-1/TLR-4 pathway axis and improve IRI-induced inflammatory damages in the liver. This is the first study to demonstrate the mechanism of the anti-inflammatory effect of rTM, especially in relation to TLR-4, and demonstrate the antiinflammatory effect of rTMD1 on liver IRI.
Materials and Methods

Animals
Male C56BL/6 mice (8-10 weeks old weighing 20 to 25 g) were purchased from Shimizu Laboratory Supplies (Kyoto, Japan). TLR-4 KO mice were purchased from Oriental Bioservice (Kyoto, Japan). All animals were kept in specific pathogen-free conditions and received humane care according to the Guide for Care and Use of Laboratory Animals. All experimental protocols were approved by the Animal Research Committee of Tazuke Kofukai Medical Research Institute at Kitano Hospital.
Reagents
Asahi Kasei Pharma (Tokyo, Japan) provided rTM and rTMD1 for this study ( Figure S1 ). Recombinant human HMGB-1 was purchased from Biolegend (San Diego, CA).
Liver IRI model
We used the established mouse model of partial warm hepatic IRI (16) (17) (18) . Mice were anesthetized under isoflurane and injected with heparin (100 U/kg). An atraumatic clip was used to interrupt the artery and portal venous supply to the left middle liver lobes. After 60 min of ischemia, the clamp was removed and reperfusion was initiated. Mice were given an intravenous injection of rTM (2, 5 , and 20 mg/kg; 5 mg/kg was optimal) or rTMD1 dissolved in saline 30 min prior to ischemic insult based on previous studies (14) ; they were then humanely killed at different time points after reperfusion. Control mice received ischemic insult as well but were treated with saline instead of rTM (n = 12 wild-type [WT] and n = 6 TLR-4 KO mice in each group). Sham-operated mice underwent the same procedure but without vascular occlusion ( Figure S2 ).
Hepatocellular function
The serum alanine aminotransferase (sALT) level in peripheral blood, an indicator of hepatocellular injury, was measured by a standard spectrophotometric method with an automated clinical analyzer (JCA-BM9030, JEOL Ltd., Tokyo, Japan).
Histology
Liver paraffin sections (5 lm thick) were stained with hematoxylin and eosin. The severity of liver IRI (necrosis, sinusoidal congestion and centrilobular ballooning) was blindly graded with modified Suzuki criteria on a scale of 0 to 4 (19) .
Enzyme-linked immunosorbent assay (ELISA)
The serum HMGB-1 level was quantified with an HMGB-1 ELISA Kit II (Shino-Test, Tokyo, Japan). The culture medium of peritoneal macrophages was analyzed for tumor necrosis factor (TNF) a using an ELISA kit (R&D Systems, Minneapolis, MN).
Quantitative reverse-transcription polymerase chain reaction (qPCR)
Total RNA was extracted from liver tissue with NucleoSpin RNA (TAKARA BIO, Kusatsu, Japan). Complementary DNA was prepared using a PrimeScript RT Reagent Kit (TAKARA BIO). Quantitative polymerase chain reaction (PCR) was performed using the StepOnePlusTM Real-Time PCR System (Life Technologies, Tokyo, Japan). Primers used to amplify specific gene fragments are listed in Table S1 . Target gene expression was calculated by the ratio to the housekeeping gene glyceraldehyde-3-phosphate (GAPDH).
Western blot assay
Proteins (20 lg/sample) from the liver were subjected to 8-16% gradient sodium dodecylsulfate (SDS)-polyacrylamide gel electrophoresis and transferred to the polyvinylidene diflouride (PVDF) membrane (Bio-Rad, Hercules, CA). Monoclonal rabbit antimouse IkBa, phosphorylated inhibitory protein of NF-kB (p-IkBa), cleaved caspase-3, Bcl-2, p-c-Jun NH2-terminal kinase (JNK), extracellular signal-regulated kinase (Erk)1/2 and HMGB-1 were purchased from Cell Signaling Technology (Danvers, MA). Monoclonal rabbit anti-caspase-1 was purchased from Abcam (Cambridge, MA). Monoclonal mouse antimouse TLR-4 antibody, polyclonal rabbit antimouse nod-like receptor protein 3 (NLRP-3) antibody were purchased from Novus Biologicals (San Diego, CA). Rabbit polyclonal antimouse JNK, p-Erk1/2 were purchased from Cell Signaling Technology. B-actin antibody was purchased from MBL (Nagoya, Japan). The intensity of the bands was quantified with Image J Software (National Institutes of Health, Bethesda, MD).
Apoptosis assay
Apoptosis in 5-lm liver paraffin sections was detected by the terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nickend labeling (TUNEL) method using an in situ Apoptosis Detection Kit (TAKARA BIO) according to the manufacturer's instructions.
Cell cultures
Thioglycollate-elicited peritoneal macrophages were collected 4 days after intraperitoneal injection of 1.5 mL 4% Brewer thioglycollate medium (Sigma-Aldrich, St. Louis, MO) by peritoneal washout with RPMI 1640 medium. Extracted cells were counted and suspended in RPMI 1640 medium containing 10% fetal bovine serum (FBS) and 2 mmol/L of glutamine. Macrophages were plated at 7.5 9 10 5 cells/well in a volume of 0.5 mL/well into 24-well cell culture plates and incubated in a humidified atmosphere of 5% CO 2 and 95% air. After 3 h, wells were washed with phosphate-buffered saline (PBS) (À) 3 times to remove floating cells, and cells were treated with or without recombinant human HMGB-1 (1 and 5 lg/mL) and rTM (50 and 250 lg/mL) (n = 3-4 in each group). Fortyeight hours after treatment, supernatants were collected and stored at À80°C until measurement for cytokines by ELISA.
Statistical analysis
All data are expressed as the means AE the standard error of the mean. Differences between experimental groups were analyzed using one-way analysis of variance of Student's t-test for unpaired data. All differences were considered statistically significant at the p-value of less than 0.05.
Results
Pretreatment with rTM improved IRI-triggered hepatocellular damage First, to elucidate the function of rTM during liver IRI, the mouse partial warm hepatic IRI model (16, 17) was used.
The rTM was intravenously administered to WT mice 30 min prior to the ischemic insult. The sALT levels at 6 h after reperfusion were decreased in the rTMpretreated group (rTM: 5 mg/kg) compared with the group without rTM administration ( Figure 1A ). The livers in rTM-treated mice showed histological improvement in lobular edema, congestion, ballooning and hepatocellular necrosis, as shown in Figure 1 (B). Suzuki's score was also significantly lowered in mice that received rTM administration ( Figure 1C ). As IR insult induces apoptosis in hepatocytes (20) (21) (22) , we examined whether rTM treatment affects the liver cell apoptosis induced by IR (Figure 1D ). The number of TUNEL-positive cells induced by IR insult were significantly decreased in rTM-treated mice compared with control mice without rTM administration. Western blot analysis revealed that treatment with rTM suppressed expression of cleaved caspase-3 but significantly increased Bcl-2 expression, which is anti-apoptotic protein, compared with mice not treated with rTM ( Figures 1 and S3 ).
Pretreatment with rTM suppressed production of proinflammatory cytokines and chemokines induced by IR in liver Inflammatory cytokines play a key role in the development of liver IRI (23) . Moreover, CXC chemokines such as CXCL-1 and CXCL-2, which are neutrophil chemoattractants, are crucial in the pathophysiology of liver IRI in mice (24) . Therefore, the effects of rTM treatment on the expression of proinflammatory cytokines (TNF-a, IL-6 and IL-1b) and chemokines (CXCL-1 and CXCL-2) were examined by qPCR in livers with IRI. The rTM treatment significantly decreased the amounts of inflammatory cytokines and chemokines induced by IR compared to the group without rTM treatment (Figure 2 ). These reductions of inflammatory cytokines and chemokines, including both CXCL-1 and CXCL-2, appeared to facilitate the improvement of the hepatic inflammation.
Intracellular translocation and serum levels of HMGB-1 in IR-treated mice suppressed by rTM
In inflammatory cells such as macrophages or necrotic cells, HMGB-1 is known to translocate from the nuclei to the cytoplasm and subsequently be released into the extracellular space (25, 26) . HMGB-1 released into the extracellular space causes the production of inflammatory cytokines. To investigate whether the intracellular translocation of HMGB-1 from the nuclei to the cytoplasm during IR insult and HMGB-1 cause IRI, cytoplasmic fractions of whole liver tissues were extracted at various time points during IR insult. The amounts of cytoplasmic HMGB-1 as well as serum levels steadily increased immediately after reperfusion. In contrast, rTM pretreatment markedly reduced HMGB-1 levels in serum as well as cytoplasm both 1 and 6 h after reperfusion ( Figures 3A, 4C and S4 ). These results clearly indicate that the translocation from the nuclei to the cytoplasm and the secretion of HMGB-1 were markedly enhanced after IR insult; rTM treatment clearly suppressed the translocation as well as the release of HMGB-1 induced by IR.
In addition to the apoptosis induced in IR insult, as shown in Figure 1 (D), pyroptosis has also been detected in the liver after IR insult and has been shown to cause HMGB-1 release through the activation of inflammasome (27) . In order to clarify the involvement of pyroptosis in the accumulation of HMGB-1, the levels of NLRP-3 and cleaved caspase-1 (p-20) were examined. Western blot analysis revealed that the expression of NLRP-3 and cleaved caspase-1 increased during ischemia and early after reperfusion as compared to the sham-operated group (lower panel of Figure 3B ). The expression of NLRP-3 was suppressed 1 h after reperfusion when rTM was administered before ischemia. These results indicate that rTM can also prevent pyroptosis as well as apoptosis in liver IR.
IR-induced upregulation of TLR-4 expression and activation of TLR-4 signaling pathway was suppressed by rTM TLR-4 activates NF-jB and the mitogen-activated protein kinase (MAPK) signaling pathway through two distinct pathways: the myeloid differentiation primary response 88 (Myd88)-dependent pathway and the interferon regulatory factor 3 (IRF-3)-dependent pathway (28) . To investigate the TLR-4-mediated signaling pathway during IR and the effect of rTM, western blotting analysis of mouse liver lysates was performed after IR. Expression of TLR-4 was clearly upregulated 0.5 h after reperfusion, and this lasted, even after 6 h. Upregulation of TLR-4 was significantly suppressed by rTM treatment (Figures 3B , S5 and S6). The amounts of phosphorylated IjBa (p-IjBa) and phosphorylated MAPKs such as p-Erk and p-JNK were similar or slightly increased immediately after the ischemic stage compared to the sham-operated group, as shown in Figure 3 
Effect of rTM depends on existence of TLR-4 system
In liver IRI, HMGB-1 has also been identified as the key endogenous TLR-4 ligand (4). To clarify the relationship among the TLR-4, HMGB-1, and rTM effects in liver IRI, we established the liver IRI model in TLR-4 KO mice. According to previous studies (2, 4, 16) , the liver damage due to IR was significantly suppressed in TLR-4 KO mice compared to WT mice ( Figure 4A ). The serum levels and cytoplasmic expression of HMGB-1 were also lower in TLR-4 KO mice compared to WT mice after reperfusion. Although rTM treatment improved the IR damage in WT mice, it did not have a favorable effect on the serum or cytoplasmic HMGB-1 levels in IR-treated TLR-4 KO mice ( Figures 4B and C) , even though significant damage still remained, as shown in Figure 4 normalized to GAPDH Figure 2 : rTM pretreatment-suppressed NF-jB and proinflammatory cytokines and chemokines. Quantitative reverse transcription-polymerase chain reaction detection of proinflammatory cytokines (TNF-a, IL-6, IL-1b, CXCL-1, and CXCL-2) at 6 h of reperfusion after 60 min of ischemia with or without rTM. Data were normalized to GAPDH gene expression (n = 6-8 mice/group; *p < 0.05, **p < 0.01). rTM, recombinant human thrombomodulin; NF-jB, nuclear factor kappa B; GAPDH, glyceraldehyde-3-phosphate; IRI, ischemia reperfusion injury; TNF-a, tumor necrosis factor a.
suppression of mouse liver IRI by rTM is fully dependent on the presence of TLR-4. Pyroptosis due to IRI was suppressed by rTM and was also fully dependent on the TLR-4 system, as the expression of NLRP-3 was slightly detected in TLR-4 KO mice ( Figure 4D ).
Production of inflammatory cytokines induced by HMGB-1 in macrophages in vitro suppressed by rTM
In order to clarify how rTM affects the HMGB-1-induced production of inflammatory cytokines such as TNF-a, we further analyzed peritoneal CD11b-positive macrophages treated with HMGB-1 ( Figure 5 ). Peritoneal macrophages from WT mice were cultured with 0 (control), 100 or 1000 ng/mL of recombinant HMGB-1 for 48 h. The addition of HMGB-1 significantly increased TNF-a levels in a dose-dependent manner. The addition of rTM at the concentration of 250 lg/mL, together with 1 or 5 lg/mL of HMGB-1, clearly reduced production of TNF-a. Peritoneal macrophages from TLR-4 KO mice were incubated with 1 or 5 lg/mL HMGB-1 and 50 or 250 lg/mL rTM for 48 h. Surprisingly, HMGB-1-induced TNF-a production was not observed at all in peritoneal macrophages from TLR-4 KO mice (right side of Figure 5 ). These results indicate that HMGB-1-induced inflammation in macrophages is fully dependent on the presence of TLR-4. by rTM in macrophages was only evident in the presence of TLR-4. This is consistent with the suppressive effects on liver IRI by rTM being observed in only a TLR-4-dependent manner (Figure 4) , suggesting that the amelioration of IRI exhibited by rTM pretreatment may be due to the downregulation of TLR-4 signaling in liver macrophages through either the rTM-mediated suppression of HMGB-1 production or interference with the interaction of TLR-4 with HMGB-1. This is followed by the suppression of inflammatory cytokines in the liver and the protection of hepatocytes from apoptosis, as well as pyroptosis induced by IR insult.
Suppression of HMGB-1-induced inflammatory cytokines
IR-triggered hepatocellular damage was suppressed by rTMD1 similarly to rTM treatment Along with an anti-inflammatory effect, rTM possesses an anticoagulant effect (11, 15) . The domain of rTMD1 has been shown to play an important role in the antiinflammatory effect of rTM (15, 29) . Thus, we tested the protective activity of rTMD1 on mouse liver IRI. Pretreatment with rTMD1 clearly decreased the levels of sALT ( Figure 6A ), liver damage ( Figures 6B and C) and the serum levels of HMGB-1 ( Figure 6D ) in IR-induced mice compared to treatment with the entire molecule of rTM. This result indicates that rTM improves IR-induced damage, mainly through the anti-inflammatory effect of lectinlike domain 1, but not through other domains responsible for anticoagulant or anti-inflammatory functions.
Discussion
This study demonstrates the therapeutic effect and mechanism of rTM on partial warm hepatic IRI in mice. Pretreatment with rTM clearly improved IRI through the amelioration of hepatocellular damage, downregulated production of proinflammatory cytokine/chemokine, reduction of apoptosis, decreased HMGB-1 expression and secretion. These changes were consistent with the downregulation of NF-jB activation induced by rTM pretreatment. Importantly, this is the first study clarifying the anti-inflammatory effect of rTM against innate immunity-dominated liver tissue damage in a TLR-4 pathway-dependent manner.
It has already been well documented that the TLR-4-NFjB pathway is critical in liver IRI (16, 30, 31) . Indeed, TLR-4 KO mice had lesser degree of liver injury and almost no activation of NF-jB in IR insult (Figures 3 and 4) . Interestingly, the state of liver injury in wild-type (WT) mice pretreated with rTM was similar to that of TLR-4 KO mice. These results indicate that TLR-4-dependent activation of NF-jB in liver IRI worsens liver damage and that rTM improves IRI by suppressing the TLR-4 signaling pathway. Moreover, HMGB-1 is reported to be the key endogenous ligand of TLR-4 responsible for immune activation in inflammations such as IRI, although several endogenous TLR-4 ligands have been identified (32) . It has been reported that the blockade of HMGB-1 by anti-HMGB-1 antibody could protect liver IRI (4, 33) and that TLR-4 antagonist attenuated liver IRI (34) . In a recent report, the redox status of three cysteine residues determined the extracellular properties of HMGB-1. HMGB-1-with a Cys23-Cys45 disulfide bond and reduced Cys106-specifically bound to myeloid differentiation factor 2 (MD-2) and activated macrophages through TLR-4 signaling (35) . Therefore, it is reasonable to examine the crosstalk between HMGB-1 and TLR-4 in order to understand the mechanism of IRI in the liver.
The rTM treatment suppressed IR-induced hepatocellular damage, as evidenced by decreased sALT levels, decreased histological features of liver injury and apoptosis induction (Figure 1) . One of the striking effects of the pretreatment with rTM was the decreased activation of NF-jB and JNK and the reduction of mRNA of proinflammatory cytokines (Figures 2 and 3) . In particular, apoptosis is an important event following liver reperfusion, the severity of which correlates with the degree of local injury (36) . The rTM treatment showed decreased frequency of TUNEL-positive cells, accompanied by decreased cleaved caspase-3 expression. We have concluded that there are three possibilities by which rTM treatment suppresses apoptosis induced by IR. First, rTM can regulate apoptosis secondary to the reduction of extracellular inflammatory cytokines, as TNF-a is reported to be a crucial factor of apoptotic cell death in IRI (20) . Second, the regulation of JNK can directly suppress the mitochondrial apoptotic pathway. Previous studies have shown that activated JNK directly affects mitochondrial apoptosis (37), and it has been shown that JNK inhibitors increase survival in a warm IR by reduction of proapoptotic protein (38) . Our data, which show that the phosphorylation of JNK induced by IR was suppressed by rTM ( Figure 3B ), suggest the possibility that rTM may also affect mitochondrial apoptosis as well as apoptosis induced by inflammatory cytokines, leading to IR-induced liver injury. Furthermore, as it has previously been reported that rTM activates the phosphatidylinositol-3 0 -kinase (PI3K)/Akt survival pathway (39, 40) , this is consistent with the upregulation of Bcl-2, as shown in Figure 1(E) , as a consequence of the activation of the PI3K/Akt pathway.
The question arises as to how rTM suppresses IRinduced TLR-4 signaling. In the present study, the insult due to IR caused the translocation of HMGB-1 from the nuclei to the cytoplasm and the release of HMGB-1 to the extracellular space, as shown in both the cytoplasmic and serum HMGB-1 levels (Figure 3) . To mimic the in vivo scenario, we used a HMGB-1-stimulated cell culture system of peritoneal macrophages. The release of TNF-a upon stimulation with HMGB-1 was dependent on the presence of TLR-4 ( Figure 5 ), consistent with the finding that HMGB-1 functions as an endogenous ligand of TLR-4. However, the rHMGB-1-driven TNF-a release was not observed in macrophages from TLR-4 KO mice. The rTM suppressed the HMGB-1-driven TNF-a release of peritoneal macrophages from WT mice but not TLR-4 KO mice. Therefore, rTM may inhibit the proinflammatory effect of HMGB-1 on macrophages through direct interference with TLR-4-HMGB-1 interaction or the interference of the TLR-4-mediated signaling pathway induced Figure 5: rTM-suppressed HMGB-1-mediated activation of peritoneal macrophages in vitro. Peritoneal macrophages from WT or TLR-4 KO mice were treated with rHMGB-1 (1000 or 5000 ng/mL), and rTM (50 or 250 lg/mL) were collected for 48 h. TNF-a release was measured by ELISA (n = 3-4 samples/group; *p < 0.05, **p < 0.01, ***p < 0.001). HMGB-1, high-mobility group box 1 protein; rTM, recombinant human thrombomodulin.
by TLR-4-HMGB-1interaction. Because it has been reported that rTM suppresses the lipopolysaccharide (LPS)-induced activation of peritoneal macrophages by binding to LPS moiety and blocking interaction between LPS and TLR-4 (29), the former possibility appears to be preferable.
In TLR-4 KO mice, serum HMGB-1 levels were lower compared to those of WT mice at the steady state, and cytoplasmic HMGB-1 did not increase at 6 h after reperfusion ( Figures 3A and 4C) . Therefore, TLR-4 signaling might also regulate the intracellular translocation and extracellular release of HMGB-1, suggesting that the translocation and release of HMGB-1 are also induced in a TLR-4-dependent manner.
Recently, it was shown that HMGB-1 is released as damage-associated molecular patterns in the case of a certain kind of cell death, in which not only necrosis but pyroptosis-a form of proinflammatory programmed cell The HMGB-1 levels were impaired by treatment with rTMD1 to the same degree as treatment with rTM (n = 6 mice/group; ***p < 0.001). HMGB-1, high-mobility group box 1 protein; IRI, ischemia reperfusion injury; sALT, serum alanine aminotransferase; rTMD1, recombinant N-terminal lectin-like domain 1 of thrombomodulin.
death-also produces HMGB-1 (41) . The release of HMGB-1 into extracellular space is regulated by inflammasomes during pyroptosis (42) , and the downstream signaling of TLR-4 activates the inflammasomes (43, 44) . In the present study, the expression of NLRP-3 and activated caspase-1 was increased, particularly in ischemia and during the early phase of reperfusion time, indicating that pyroptosis occurred at an early stage in IR (Figure 3B) . The expression of NLRP-3 was dependent on TLR-4 but was not suppressed before reperfusion when pyroptosis was strongly activated (Figures 3B and 4D ). Pyroptosis could be regulated through JNK and NF-jB signaling, as JNK regulates inflammasome complex formation, leading to caspase-1 activation (45), and NLRP-3 expression is controlled by the activation of NF-jB (46) . Thus, our study indicates that HMGB-1 also stimulates proinflammatory responses in cells such as Kupffer cells or macrophages in the liver upon IR insult through TLR-4.
The protein of rTM consists of three domains: D1, D2, and D3 ( Figure S1 ) (11) . The protein of rTMD1 binds to HMGB-1 and prevents HMGB-1 from exacerbating inflammation (15) . The thrombin-thrombomodulin complex cleaves HMGB-1 to a less proinflammatory form (47) . D2 is responsible for thrombin binding and protein C activation. Activated protein C not only works as an anticoagulant factor but also has indirect inflammatory activities (48) . D-2/3 also exhibits an anti-inflammatory effect (49) , and rTM has a protective effect in the murine liver resection model (50, 51) . In our study, pretreatment with rTMD1 demonstrated the suppression of sALT and serum HMGB-1 levels in liver IRI to the same extent as rTM treatment. The use of rTMD1 and rTM could possess therapeutic potential for inflammatory diseases. Figure 7 shows the potential mechanisms by which rTM suppresses liver IRI through the prevention of macrophage activation mediated by HMGB-1. IR-triggered HMGB-1 secretion activates the TLR-4 signaling pathway, leads to the activation of NF-jB, increases the production of proinflammatory cytokines, followed by translocation and secretion of HMGB-1, and enhances TLR-4 expression. Treatment with rTM prior to IR insult suppresses the activation of the TLR-4 pathway by decreasing HMGB-1 secretion and interfering with HMGB-1-TLR-4 interaction.
In conclusion, rTM has a protective effect on liver IRI by preventing HMGB-1-TLR-4 interaction and HMGB-1 release in a TLR-4-dependent manner. The use of rTM and D1 might have therapeutic potential for liver transplantation. 
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